| Autor: |
Anderson, Scott, Reck dos Santos, Pedro, Langlais, Blake, Campany, Megan, Donato, Britton, D'Cunha, Jonathan |
| Zdroj: |
Annals of Thoracic Surgery; Apr2024, Vol. 117 Issue 4, p820-827, 8p |
| Abstrakt: |
After implementation of the Lung Allocation Score in 2005, idiopathic pulmonary fibrosis (IPF) emerged as the most common indication for lung transplantation (LT) in the United States. The age and comorbidity of patients undergoing LT have since increased, and the indications for LT have evolved. However, limited data have been used to analyze more recent outcomes among the IPF population. This study analyzed LTs for the primary indication of IPF by using the United Network for Organ Sharing database. An eras-based analysis was performed, comparing patient characteristics, survival, and related outcomes during 2005 to 2009 (era 1) and 2010 to 2014 (era 2) with χ2, Wilcoxon rank sum, and Kaplan-Meier analyses. The study compared 1-year survival from 2005 to 2020 and survival at milestones ranging from 1 month to 5 years. Two adjusted Cox proportional hazards models were conducted: 5-year survival by era and 1-year survival annually from 2010 to 2020. From era 1 (n = 1818) to era 2 (n = 3227), the median age of LT recipients increased from 61 to 63 years (P <.001). The percentage of patients in the intensive care unit before LT climbed from 7.7% to 12.1% (P <.001), and the percentage of patients with diabetes grew from 17.9% to 19.4% (P =.003). Despite increased severity of illness, 5-year survival increased from 51.9% in era 1 to 55.2% in era 2 (P =.02). Adjusted modeling indicated that LT during era 2 featured a 17% hazard reduction compared with era 1 (hazard ratio, 0.83; 95% CI, 0.76-0.91). Survival is improving for patients undergoing LT for IPF, despite the challenges of transplant recipients with progressively higher risk profiles. [Display omitted] [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
